Orchestra BioMed Holdings, Inc.
OBIO Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 27, 2026
$5.78
KIRA · Stoqly’s AI analyst, in plain words
- Orchestra BioMed Holdings, Inc. had $33.5M of revenue in fiscal 2025, up 1,169.2% on the year before.
- Its operating margin was −154.7%, up 2,282.8 pts: of every 100 in sales, about −155 is left after running the business.
- Orchestra BioMed Holdings, Inc. lost $52.7M in fiscal 2025.
- Free cash flow was −$49.5M in fiscal 2025, −147.7% of revenue.
- Orchestra BioMed Holdings, Inc. has $91.5M more cash than debt.
Market cap
$369M
P/E
—
Revenue
$33.5M
Net income
−$52.7M
Free cash flow
−$49.5M
Operating margin
−154.7%
Orchestra BioMed Holdings, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+1,169.2%
Yes. Sales grew 1,169.2% last year.
Does it make a profit?
−157.4%
No. It lost money last year.
Does profit turn into cash?
−147.7%
No. It spent more cash than it brought in.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Orchestra BioMed Holdings, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 12, 2026
- Legal name
- Orchestra BioMed Holdings, Inc.
- CIK
- 0001814114
Orchestra BioMed Holdings, Inc. · OBIO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $3.5M | $2.8M | $2.6M | $33.5M |
| Revenue growth | — | — | −21.9% | −4.4% | 1,169.2% |
| Net interest income | — | $0.1M | $3.8M | — | — |
| Gross margin | — | 94.0% | 93.3% | 92.3% | 99.4% |
| Operating margin | — | −924.3% | −1,866.2% | −2,437.5% | −154.7% |
| Net income | −$0.4M | −$33.6M | −$49.1M | −$61.0M | −$52.7M |
| Net margin | — | −951.3% | −1,779.7% | −2,313.3% | −157.4% |
| Diluted EPS | −$0.02 | −$2.24 | −$1.48 | −$1.66 | −$1.11 |
| Cash | |||||
| Cash from operations | −$0.3M | −$29.3M | −$46.1M | −$50.6M | −$49.0M |
| Capital expenditure | — | $0.6M | $0.1M | $0.3M | $0.5M |
| Free cash flow | — | −$29.9M | −$46.2M | −$50.8M | −$49.5M |
| FCF margin | — | −845.7% | −1,674.1% | −1,927.5% | −147.7% |
| Share count change | — | −26.7% | 121.7% | 10.8% | 29.7% |
| Debt and strength | |||||
| Cash and short-term investments | $1.8M | $83.7M | $87.5M | $66.8M | $107M |
| Debt incl. finance leases | — | — | — | $15.0M | $15.0M |
| Shareholders' equity | −$19.8M | $52.5M | $68.0M | $33.0M | $53.6M |
| Current ratio | 10.9x | 4.6x | 8.0x | 4.3x | 6.4x |
| Interest coverage | — | −25.1x | −36.8x | −216.5x | — |
| Returns and quality | |||||
| Return on equity | — | −205.2% | −81.5% | −120.8% | −121.8% |
| Return on tangible equity | — | −64.0% | −72.2% | −185.2% | −98.9% |
| Piotroski F-score | — | — | 2 | 2 | 6 |
| Altman Z'' | −3.6 | −3.3 | −4.2 | −13.6 | −7.0 |
Insiders bought, 12 months
$0.3M
4 insiders
Insiders sold, 12 months
$0.4M
2 insiders
Of sales under plans
100%
$0.4M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Orchestra BioMed Holdings, Inc. · OBIO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.78 a share, the company is worth $369M.
Source: SEC EDGAR XBRL filings (CIK 0001814114). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.